Safety and efficacy of tacrolimus in pediatric liver recipients

Pediatric Transplantation

Volumn 15, Issue 1, 2011, Pages 19-24

  Kelly, Deirdre ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

immunosuppression; liver transplantation; pediatric transplantation; tacrolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLERGIC ECZEMA; ALOPECIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHILD; CHRONIC GRAFT REJECTION; CUSHINGOID SYNDROME; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; GRAFT SURVIVAL; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEUROTOXICITY; PEDIATRICIAN; PEDIATRICS; PREGNANCY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; STEROID THERAPY; WEIGHT GAIN;

ADOLESCENT; ADULT; CHILD; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEROIDS; TACROLIMUS; TREATMENT OUTCOME;

EID: 78751657726     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01437.x     Document Type: Article

References (20)

1. Soltys KA, Mazariegos GV, Squires RH, Sindhi RK, Anand R,. Late graft loss or death in pediatric liver transplantation: An analysis of the SPLIT database. Am J Transplant 2007: 7: 2165-2171.
2. Wallot MA, Mathot M, Janssen M, et al. Long-term survival and late graft loss in pediatric liver transplant recipients-A 15-year single-center experience. Liver Transpl 2002: 8: 615-622.
3. Becker J, Huber WD, Aufricht C,. Short- and long-time effects of pediatric liver transplantation on serum cholesterol and triglyceride levels-The Vienna cohort. Pediatr Transplant 2008: 12: 883-888.
4. Sudan DL, Shaw BW Jr, Langnas AN,. Causes of late mortality in pediatric liver transplant recipients. Ann Surg 1998: 227: 289-295.
5. Stolberg HO, Norman G, Trop I,. Randomized controlled trials. Am J Roentgenol 2004: 183: 1539-1544.
6. McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. Transplantation 1995: 59: 530-536.
7. Jain A, Mazariegos G, Kashyap R, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation 2000: 70: 617-625.
8. Kelly DA, Jara P, Rodeck B, et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: Randomised European multicentre trial. Lancet 2004: 364: 1054-1061.
9. Kelly DA, Lloyd C, Jara P, et al. Long term follow up of children receiving tacrolimus (Tac) or cyclosporin A-ME (CyA) post liver transplantation (OLT). Pediatr Transplant 2007: 11: 110.
10. Hasenbein W, Albani J, Englert C, et al. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. Pediatr Transplant 2006: 10: 938-942.
11. Shepherd RW, Turmelle Y, Nadler M, et al. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008: 8: 396-403.
12. Reding R, Gras J, Sokal E, Otte JB, Davies HF,. Steroid-free liver transplantation in children. Lancet 2003: 362: 2068-2070.
13. Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006: 6: 1913-1921.
14. Gras JM, Gerkens S, Beguin C, et al. Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: Clinical and pharmacoeconomic study in 50 children. Liver Transpl 2008: 14: 469-477.
15. Calne R,. "Prope" tolerance: Induction, lymphocyte depletion with minimal maintenance. Transplantation 2005: 80: 6-7.
16. Reding R, Pire A, Janssen M, et al. Steroid-free tacrolimus-based immunosuppression promotes long-term Prope/operational tolerance in pediatric liver transplantation. Pediatr Transplant 2009: 13: 63-64.
17. Tricot L, Lebbe C, Pillebou E, Martinez F, Legendre C, Thervet E,. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. Transplantation 2005: 80: 1546-1549.
18. Peters TG, Spinola KN,. Differences in patient and transplant professional perceptions of immunosuppression-induced cosmetic side effects. Transplantation 2004: 78: 537-543.
19. Coady NT,. Maternal transplantation medications during breastfeeding. J Hum Lact 2002: 18: 66-68.
20. Gardiner SJ, Begg EJ,. Breastfeeding during tacrolimus therapy. Obstet Gynecol 2006: 107 (2 Pt 2): 453-455.